American Association of Clinical Endocrinologists Announces Publication of 2018 Comprehensive Type 2 Diabetes Management Algorithm and Executive Summary

Updates Include Emphasis on Type 2 Diabetes Drugs Providing Proven Cardiovascular Benefits

Monday, January 8, 2018 8:26 am EST

Dateline:

JACKSONVILLE, Fla.
"With cardiovascular disease of particular concern with Type 2 Diabetes patients, this algorithm provides important updates regarding glucose-lowering therapies and their impact on cardiovascular outcomes"

The American Association of Clinical Endocrinologists (AACE), in conjunction with the American College of Endocrinology (ACE), today announced the online-ahead-of-print publication of the 2018 AACE/ACE Comprehensive Type 2 Diabetes (T2D) Management Algorithm.

 Available for viewing at https://www.aace.com/publications/algorithm, the 2018 algorithm is notable for its updated assessment of T2D glucose-lowering medications, particularly those with proven benefits in mitigating artherosclerotic cardiovascular disease (CVD), and includes detailed recommendations for the use of treatment agents to manage blood pressure and lipid control, the two most important risk factors for CVD.

The algorithm also features a suggested hierarchy of usage for T2D glycemic control medications based on the patient’s initial A1C as well as the strength of the recommendations based on expert analysis.

Additionally, although some T2D patients can achieve lipid profile improvements through lifestyle therapies, the algorithm recommends more intensive pharmacotherapy to reduce CVD risk for those in low and moderate risk categories. Updated treatment goals are LDL-C of <130 and non-HDL-C of <160 for moderate risk patients and LDL-C of <160 and non-HDL-C of <190 in low risk patients.

“With cardiovascular disease of particular concern with Type 2 Diabetes patients, this algorithm provides important updates regarding glucose-lowering therapies and their impact on cardiovascular outcomes,” notes Alan J. Garber, MD, PhD, FACE, chair of the AACE/ACE Comprehensive Diabetes Management Algorithm Task Force. “This comprehensive tool also provides updates on other areas of therapy to ensure optimal patient care is achieved.”